Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TaRGET: Tideglusib for Arrhythmogenic Cardiomyopathy
NCT06174220Phase 2Recruiting
- Sponsor
- Hamilton Health Sciences
- Start
- Mar 2025
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in arrhythmogenic cardiomyopathy (ACM) comparing Tideglusib with Placebo (2 arms). Primary endpoint: Premature Ventricular Complex burden at 6 months. Started Mar 2025; status: recruiting.
02
Drugs
tideglusib
03
Conditions
arrhythmogenic cardiomyopathy (ACM)
Beyond the preview
Go deeper on NCT06174220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06174220.